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ABSTRACT
The insulin-like growth factors (IGFs) have mitogenic effects on
normal and tumoral prostate epithelial cells and have been suggested
to be involved in prostate cancer. Moreover, chronic GH and IGF-I
excess causes prostate overgrowth in patients with acromegaly. This
study was designed to investigate whether the suppression of GH and
IGF-I levels by surgery or pharmacotherapy could induce the regres-
sion of prostatic hyperplasia in acromegalic patients. To this end,
prostate volume (PV) as well as the occurrence of prostatic diseases
were studied by transrectal ultrasonography in 23 untreated acro-
megalic patients (with elevated GH and IGF levels). None of the
patients reported symptoms due to prostatic disorders or obstruction.
At study entry, prostate hyperplasia was found in half patients.
After 2 yr, GH, IGF-I, and IGFBP-3 levels were decreased, whereas
prostate-specific antigen levels did not change. PV was decreased in
the 16 patients who were well controlled. Among the 6 patients with
prostate hyperplasia at study entry who achieved disease control, 4
regained a normal PV at the end of the 2 yr of treatment, whereas none
of the 5 patients with prostate hyperplasia at study entry and not
achieving disease control normalized their PV. When patients were
divided according to age, prostate volume decreased after 2 yr only in
the 8 controlled patients aged below 50 yr, but not in those controlled
and with age above 50 yr despite similar decrease in GH, IGF-I, and
IGFBP3 levels. No clinical, transrectal ultrasonography, or cytolog-
ical evidence of prostate cancer was detected during the study period.
These data suggest that hyperplasia, but not cancer, is frequent in
acromegalic men, and that the GH-IGF axis and age are indepen-
dently associated with the development of this process. (J Clin En-
docrinol Metab 85: 3754–3761, 2000)
IN RECENT YEARS the insulin-like growth factor (IGF) axishas been demonstrated to regulate prostate tissue, indicat-
ing a pivotal role of IGF-I and -II and IGF-binding proteins
(IGFBPs) on the prostate (1, 2). Both IGF-I and IGF-II have direct
mitogenic effects on several tissues, including normal and tu-
moral prostate epithelial cells and have been implicated in the
pathogenesis of prostate cancer (2–5), but their actions still need
to be clarified. GH and its effector IGF-I, mainly carried in the
plasma by IGFBP-3, are physiological promoters of somatic
growth, although in vitro and in vivo studies have raised the
concern on whether they could also regulate hypertrophic and
tumoral proliferation of various tissues, including the prostate
(2–9). The expression of IGF-I and -II, IGF receptors, and IGFBPs
was found in normal and tumoral prostatic tissue; in vitro pros-
tate cell growth is stimulated by IGF-I and inhibited by IGFBP-3
(2, 10–12). In addition, IGF-I levels were found to be directly
correlated, whereas IGFBP-3 levels inversely correlated to pros-
tate cancer risk (4, 5).
The role played by the GH/IGF-I axis on prostate growth
has also been suggested by our recent observations in acro-
megalic and GH-deficient patients. In fact, chronically ele-
vated GH, IGF-I, and IGFBP-3 levels were shown to deter-
mine prostate overgrowth and structural changes, such as
nodules, cysts, and calcifications, in a large proportion of
acromegalic patients (13, 14), whereas in long-standing GH
deficiency associated with hypogonadism, a decrease in
prostate size was found (13, 15). Prostate hyperplasia was
also found in young acromegalic patients, who were not
expected to have age-dependent prostate diseases (13, 14).
The evidence that prostate disorders occur in presence of
hypogonadism and that prostate size decreases after 1 yr of
treatment with octreotide in a small group of young patients
(14), further supports the hypothesis that chronic GH/IGF-I
excess causes prostate hyperplasia.
To better understand whether the control of GH and IGF-I
excess by surgery and/or pharmacotherapy could reverse
prostatic abnormalities in acromegaly, prostate volume as
well as the occurrence of prostatic diseases were studied by
transrectal ultrasonography (TRUS) in untreated patients be-
fore and 2 yr after treatment of acromegaly. The effects on the
prostate were analyzed in patients achieving disease control
and in those still presenting with disease activity at 2 yr.
Subjects and Methods
Patients
Twenty-three acromegalic males, aged 29–70 yr (mean 6 sem, 50.0 6
2.8 yr), were enrolled in this study; they were free of previous or present
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prostate diseases and were not receiving replacement treatment with
androgen, b-adrenergic antagonists, or antiandrogen drugs. None of
them had previously experienced any episode suggesting prostate, go-
nadal, and/or urethral disorders, such as prostatitis, orchitis, inflam-
mation of seminal vesicles, or spontaneous or precipitated acute urinary
retention. The study was performed after approval of the local ethical
committee and once patients’ informed consent had been obtained. The
diagnosis of acromegaly was based on elevated GH levels not suppress-
ible below 3 mU/L by oral glucose test, high IGF-I levels compared to
age-matched controls, signs and symptoms of acromegaly, and radio-
logical evidence of pituitary adenoma (16, 17). At admission, all patients
were in active disease (GH, 117.9 6 17.7 mU/L; IGF-I, 920.1 6 60.8
mg/L). The profiles of the patients’ at their enrollment in our study is
shown in Table 1. Ten patients were mild smokers; none was a heavy
alcohol drinker, and all consumed a normal diet. All patients were
included in a previous transversal study (13).
Study design
The study protocol included hormonal tests and subsequently TRUS.
At diagnosis, serum GH was calculated as the mean of a 2-h blood
sampling (0800–1000 with 30-min sampling), whereas all of the other
hormone evaluations were performed in a single sample, as previously
reported (18). All patients except 3 underwent surgery, followed by
disease control in 9. In the remaining 14 patients, chronic treatment with
lanreotide (Ipstyl, Ipsen, Italy) was started at the initial dose of 30 mg,
im, every 14 days. The frequency of administration was increased to
every 10–7 days in 7 patients not achieving disease control. A general
clinic examination was carried out before and every 3 months during the
follow-up. During treatment, the final GH level was calculated as the
average value from at least 3 blood samples collected at 15-min intervals
just before the next im injection of LAN (19). At this time point, circu-
lating IGF-I, IGFBP-3, PRL, testosterone (T), dihydrotestosterone (DHT),
D4-androstenedione (D4), dehydroepiandrosterone sulfate (DHEA-S),
prostate-specific antigen (PSA), free PSA, and prostatic alkaline phos-
phatase concentrations were assayed as single sampling. Data were
further analyzed according to patients less than or more than (in 12 and
11) 50 yr of age. No patient received T replacement.
Hormonal assessment
Circulating GH, IGF-I, PRL, FSH, LH, T, DHT, D4, DHEA-S, PSA, free
PSA, and prostatic alkaline phosphatase levels were assayed using com-
mercially available kits. The cut-off values of 7.5 and 4 mg/L were
considered the upper limits for GH and PSA concentrations, respec-
tively. The calculation of PSA density, expressed as the ratio of PSA
levels/prostate volume (PV) was considered a risk factor for prostate
cancer when it was higher than 0.15. All assessments were age adjusted.
Serum GH levels were measured by immunoradiometric assay (HGH-
CTK-IRMA Sorin, Saluggia, Italy). The sensitivity of the assay was 0.6
mU/L, 1 mg/L corresponds to 3 mU/L. The intra- and interassay co-
efficients of variation (CVs) were 4.5% and 7.9%, respectively. Plasma
IGF-I was measured by immunoradiometric assay after ethanol extrac-
tion using kits from Diagnostic Systems Laboratories, Inc. (Webster, TX).
The sensitivity of the assay was 0.8 mg/L. The intraassay CVs were 3.4%,
3.0%, and 1.5% for the low, medium, and high points on the standard
curve, respectively. The interassay CVs were 8.2%, 1.5%, and 3.7% for
the low, medium, and high points on the standard curve. Plasma
IGFBP-3 was measured by RIA after ethanol extraction using kits from
Diagnostic Systems Laboratories, Inc. The sensitivity of the assay was 0.5
mg/L. The intraassay CVs were 3.9%, 3.2%, and 1.8% for the low, me-
dium, and high points on the standard curve, respectively. The inter-
assay CVs were 0.6%, 0.5%, and 1.6% for the low, medium, and high
points on the standard curve.
TRUS study
Before TRUS, all 23 subjects received a preliminary enema with 200
mL sorbitol and a digital rectal exploration. TRUS was performed by
means of an ATL Apogee 800 (Advanced Technology Laboratories,
Bothell, WA) and a 9.0-MHz end-fire transrectal transducer with power
echo color doppler module to display prostate angiographic micromaps
(20). The transducer, preliminarily covered with ultrasound transmis-
sion gel (Acquasonic, Parker Laboratory, Newark, NJ) and a disposable
rubber sheath, was lubricated and gradually inserted about 3 cm into the
rectum, then directed toward the anterior rectal wall. The prostate ex-
amination covered the antero-posterior, transversal, and cranio-caudal
diameters; the transitional zone; the morphology of boundaries; and the
occurrence of calcifications and nodules. Seminal vesicles were imaged,
and inflammatory events, not previously reported by the patients, were
also investigated. The PV and the volume of the transitional zone were
calculated by means of the standard ellipsoid formula (0.52 3 antero-
posterior diameter 3 transversal diameter 3 cranio-caudal diameter).
Echo-guided prostate biopsies with power Doppler enhancement were
performed if clinical or hormonal conditions required it. All scans were
performed by the same investigator (S.S.), who was blind with respect
to patients’ responses to treatment. Prostate hyperplasia was considered
for PV exceeding 30 mL according to accepted criteria for benign pros-
tate hyperplasia (21, 22).
Statistical analysis
Data are expressed as the mean 6 sem. ANOVA, followed by the
Newman-Keuls test, and Student’s t test for paired data were applied
where appropriate. Statistical significance was set at 5%.
Results
Hypogonadism, based on low T and DHT levels, was
present in 13 (56.5%) patients. Four untreated patients had
hyperprolactinemia (serum PRL ranging from 480–17220
mU/L; Table 1), and no abnormalities in DHEA-S levels were
found in any patient. None of the patients had elevated PSA
levels, whereas PSA density was high in 1 patient. Symptoms
due to prostatic, seminal vesicle, and/or urethral disorders
or obstruction were not seen in any patient. Digital rectal
examination revealed no occurrence of prostatic nodules or
other abnormalities. Hormone and prostate characteristics
before and after treatment in the 23 patients are shown in
Table 2. Prostate hyperplasia was found in 11 patients (no.
4, 8–10, 12, 13, 15, 18, 19, 22, and 23; Table 1). Similarly, an
increased median lobe was observed. In fact, the transitional
zone was measurable in all acromegalics, ranging from 1.3–
25.8 mL (Table 2).
After 2 yr, control of acromegaly was achieved in 16 of 23
patients (Fig. 1 and Table 3). Nine patients achieved disease
control by surgery alone, whereas the other 7 patients were
treated with 60–90 mg/month lanreotide, im, achieving sus-
tained GH/IGF-I suppression. Conversely, in the remaining
7 patients, GH and IGF-I levels remained slightly elevated
during the follow-up despite using increasing doses of lan-
reotide (Table 3). In controlled patients, both T and DHT
levels were significantly increased compared to basal values
(Table 3), and among the 10 hypogonadal patients at study
entry, 7 regained normal T and DHT levels. After 2 yr, the
TRUS-measured prostate size was significantly reduced
compared to the baseline in these 16 patients (P 5 0.03; Table
3), whereas no difference was found in D4, DHEA-S, and PSA
levels; PSA density; or the volume of the transitional zone
(Table 3). No difference in PV decrease was found between
patients controlled by surgery alone (from 38.3 6 5.2 to 32 6
3.7 mL) and those controlled by surgery and/or lanreotide
or lanreotide alone (from 25.8 6 3.4 to 21.6 6 2 mL). In these
2 subgroups, similar decreases in GH (Fig. 1), IGF-I (from
884.8 6 63.4 to 223.1 6 41.1 and from 911.3 6 113.8 to 236.0 6
28.2 mg/L, respectively), and IGFBP-3 levels (from 5.7 6 0.6
to 3.6 6 0.4 and from 7.4 6 0.7 to 4.2 6 0.6 mg/L, respectively)
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were found. Among the 16 controlled, 6 patients presented
with prostate hyperplasia at diagnosis, 4 had a PV of less than
30 mL at the end of the 2-yr follow-up (Fig. 1). In contrast,
no change in T and DHT levels or in whole prostate (Fig. 1)
and transitional zone volumes was observed in the 7 patients
with uncontrolled disease during the follow-up (Table 3). In
particular, hypogonadism and prostate hyperplasia, which
were present in 3 and 5 patients at study entry, respectively,
were not found in any of the patients.
As prostate size is known to increase with age, the change
in PV was analyzed in the 16 patients achieving disease
control and in the 7 uncontrolled patients, grouped accord-
ing to age below or above 50 yr. In the 8 controlled patients
less than 50 yr of age, T and DHT levels and PV significantly
decreased after 2 yr (Fig. 2). This was associated with a
decrease in IGF-I levels (Fig. 2), GH (from 111.3 6 22.2 to
4.5 6 1.2 mU/L; P 5 0.002), and IGFBP-3 levels (from 7.8 6
0.6 to 4.7 6 0.4 mg/L; P 5 0.0002). In the 8 patients more than
50 yr of age, no significant change in T and DHT levels or PV
was observed despite similar decreases in IGF-I levels (Fig.
2), GH (from 130.8 6 46.2 to 3.6 6 0.6 mU/L; P 5 0.03) and
IGFBP-3 (from 5.2 6 0.5 to 2.9 6 0.3 mg/L; P 5 0.0001).
Among the 7 uncontrolled patients, no change was found in
the dimension of the whole prostate and the transitional zone
in the 4 patients less than 50 yr of age (from 28.5 6 3.9 to
35.7 6 5.6 and from 4.4 6 1.3 to 6.4 6 1.7 mL) or in the
remaining 3 more than 50 yr of age (from 71.3 6 8.8 to 67.6 6
11.9 and from 19.9 6 3.1 to 20.6 6 3.9 mL). However, it should
be noted that elderly patients with uncontrolled disease had
the greatest size of whole prostate (Figs. 1 and 3) and tran-
sitional zone at study entry.
Structural abnormalities, including calcifications, nodules,
cysts, and vesicles inflammation, were found in 17 patients
(73.9%): no significant changes were observed at the end of
treatment. No clinical, TRUS, or cytological evidence of pros-
tate cancer was detected during the 2-yr study period.
Discussion
In acromegaly, prolonged hypersecretion of GH and IGF-I
constantly causes enlargement of most internal body organs,
including thyroid, heart, liver, bone (16, 18, 23, 24), and
prostate (13, 14). Our preliminary results obtained in more
than 70 acromegalic men clearly demonstrated that these
patients have an increased prevalence of prostate disorders
compared to age-matched control subjects, mainly because of
an increased size of the whole prostate and the transitional
zone, together with an elevated incidence of nodules and
calcifications (13, 14). It is still controversial whether IGF-I
levels are directly correlated to an increased risk for prostate
cancer, as some studies are in line with (4, 5), and another
denies (25) this hypothesis. Among our patients, in both the
previous series (13, 14) and the present one, no occurrence of
prostate cancer was observed. Notably, in patients with GH
deficiency, PV was decreased when compared to that in
age-matched healthy controls overall when concomitant hy-
pogonadism existed (13, 15). This finding is easily explained
considering the well known evidence of direct and indirect
regulatory effects of androgens on prostatic cell growth and
differentiation (26, 27). On the other hand, an up-regulation
of IGF-I receptor expression on prostatic epithelial cells was
documented in patients with prostate hypertrophy treated
with gonadotropin-releasing analogs (28). This suggested the
existence of important cross-talk among androgens, growth
factors, and IGFBPs at the prostatic level (29). Moreover, a
decrease in intraprostatic IGF-I levels together with in-
creased levels of IGFBP-2, -4, and -5 have been recently
reported in men with benign prostate hyperplasia treated
with finasteride (30). In this light, acromegalic patients can
be considered as a peculiar study model, as they often
present with overt hypogonadism (56.5% of the present se-
ries), but prostatic enlargement that particularly affects the
median lobe is recorded in a high proportion of patients (13)
TABLE 2. Hormone levels and ultrasonographic evaluation of
prostate parameters in the 23 patients before and after 2 yr of
treatment of acromegaly
Parameter Baseline 2 yr aftertreatment P
GH levels (mU/L)
Range 23.4–429 0.3–111
Mean 6 SEM 117.9 6 17.7 15.9 6 6.0 ,0.0001
IGF-I levels (mg/L)
Range 553–1600 50–850 ,0.0001
Mean 6 SEM 920.1 6 60.8 342.6 6 46.4 ,0.0001
IGFBP-3 levels
(mg/L)
Range 3.2–9.2 2.1–6.5
Mean 6 SEM 5.9 6 0.4 4.0 6 0.3 ,0.0001
PRL levels (mU/L)
Range 30–17220 0.3–1500
Mean 6 SEM 1197.0 6 747 10.5 6 2.5 0.2
Testosterone levels
(mg/L)
Range 0.8–5.0 0.9–10
Mean 6 SEM 2.5 6 0.3 4.0 6 0.3 0.02
DHT levels (nmol/L)
Range 0.10–0.80 0.11–0.95
Mean 6 SEM 0.39 6 0.04 0.53 6 0.05 0.002
D4 levels (mg/L)
Range 0.7–4.6 0.1–6.1
Mean 6 SEM 2.2 6 0.2 2.2 6 0.3 0.9
DHEA-S levels
(mg/L)
Range 15–746 20–358
Mean 6 SEM 185.7 6 20.4 175.6 6 20.6 0.6
PSA levels (mg/L)
Range 0.1–2.1 0.2–4.2
Mean 6 SEM 0.86 6 0.08 1.18 6 0.21 0.2
PSA density
Range 0.006–0.37 0.008–0.08
Mean 6 SEM 0.042 6 0.01 0.035 6 0.005 0.2
Prostate volume
(mL)
Range 15.7–84.3 11.7–80.5
Mean 6 SEM 34.6 6 3.7 32.5 6 4.0 0.3
Transitional zone
vol (mL)
Range 1.3–25.8 0.9–26.7
Mean 6 SEM 6.5 6 1.3 7.8 6 1.5 0.1
Normal ranges: GH, ,7.5 mU/L; IGF-I, 100–402, 90–258 mg/L for
patients aged ,50 and .50 yr, respectively; IGFBP-3, 2.1–6.5 and
2–4 mg/L, for patients aged ,50 and .50 yr, respectively; PRL,
150–450 mU/L; testosterone, 3.5–9 mg/L; dihydrotestosterone (DHT),
0.4–1.6 nmol/L; D4, 1–3.5 mg/L; DHEA-S, 60–560 mg/L; PSA, 0–4
mg/L; prostate volume, ,30 mL. According to a previous study (13),
normal transitional zone volumes were 2.4 6 0.4, 3.0 6 0.3, and 5.8 6
0.6 mL for healthy controls aged ,40, 40–60 and .60 yr.
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FIG. 1. Serum GH profile (left) and PV measured by TRUS (right) before and after 2 yr of follow-up in the nine patients controlled by surgery
(top), in the seven patients controlled by lanreotide (middle), and in the seven uncontrolled patients (bottom).
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and in 47.8% of those included in the current study. There-
fore, although adequate levels of androgens are necessary in
early developmental stages, IGF-I and GH are also required
for prostate gland development (31), and in the acromegalic
male prostate, overgrowth seems to rely on chronic GH and
IGF-I excess.
The pivotal role played by the chronic excess of GH and
IGF-I in prostate overgrowth was also indicated by the sig-
nificant decrease in PV obtained after 2 yr of treatment of the
primary disease by surgery and/or lanreotide in the 16 pa-
tients who achieved successful GH/IGF-I suppression. As
further support, in the 7 patients presenting with mild dis-
ease activity during the 2-yr follow-up, the levels of T and
DHT and both the volume of the whole prostate and that of
TABLE 3. Hormone levels and ultrasonographic evaluation of prostate parameters before and after 2 yr of treatment of acromegaly in
the 23 patients grouped in line to the response to treatment
Parameter
Patients well controlled (n 5 16) Patients not controlled (n 5 7)
Basal Treatment P Basal Treatment P
Age (yr) 49.9 6 3.3 / 50.1 6 5.7 /
GH (mU/L) 121.2 6 24.9 4.2 6 0.6 ,0.0001 110.7 6 15.6 43.8 6 15.3 0.002
IGF-I (mg/L) 896.4 6 63.4 223.1 6 59.0 ,0.0001 974.1 6 154.8 602.9 6 77.6 0.04
IGFBP-3 (mg/L) 6.4 6 0.5 3.9 6 0.4 ,0.0001 4.6 6 0.6 4.4 6 0.5 0.6
PRL (mU/L) 555.0 6 237 282.0 6 75 0.1 2664.0 6 2340 260.0 6 184 0.3
Testosterone (mg/L) 2.3 6 0.3 4.7 6 0.6 0.02 2.9 6 0.4 2.5 6 0.4 0.5
DHT (nmol/L) 0.35 6 0.05 0.52 6 0.05 0.003 0.49 6 0.09 0.55 6 0.01 0.3
D4 (mg/L) 2.0 6 0.3 2.0 6 0.3 0.9 2.7 6 0.5 2.8 6 0.7 0.8
DHEA-S levels (mg/L) 191.3 6 24.1 154.7 6 18.3 0.6 172.7 6 40.9 223.3 6 51.6 0.2
PSA (mg/L) 0.8 6 0.1 1.1 6 0.3 0.3 0.92 6 0.1 1.34 6 0.4 0.4
PSA density 0.05 6 0.02 0.04 6 0.006 0.5 0.02 6 0.005 0.03 6 0.009 0.4
Prostate vol (mL) 29.3 6 2.6 25.4 6 3.1 0.03 46.9 6 9.5 48.8 6 8.6 0.8
Transitional zone vol (mL) 4.6 6 0.8 5.8 6 1.5 0.2 11.0 6 3.4 12.5 6 3.3 0.1
Normal ranges: GH, ,7.5 mU/L; IGF-I, 100–402, 90–258 mg/L for patients aged ,50 and .50 yr, respectively; IGFBP-3, 2.1–6.5 and 2–4
mg/L for patients aged ,50 and .50 yr, respectively; PRL, 150–450 mU/L; testosterone, 3.5–9 mg/L; dihydrotestosterone (DHT), 0.4–1.6 nmol/L;
D4, 1–3.5 mg/L; DHEA-S, 60–560 mg/L; PSA, 0–4 mg/L; PSA density, ,0.15; prostate volume, ,30 mL. According to a previous study (13), normal
transitional zone volumes were 2.4 6 0.4, 3.0 6 0.3, and 5.8 6 0.6 mL for healthy controls aged ,40, 40–60, and .60 yr.
FIG. 2. Circulating levels of IGF-I (top left), T (top right), and DHT (bottom left) and PV (bottom right) before and after treatment in the 16
well controlled patients grouped according to age: less than 50 yr (top) and more than 50 yr (bottom).
PROSTATIC DISORDERS AFTER CURE OF ACROMEGALY 3759
 on May 8, 2005 jcem.endojournals.org
the transitional zone were unchanged. In the current series,
the prevalence of cysts and micro- and macrocalcifications
occurred in as many as 73.9% of the cases, confirming a
previous report (13), and no significant changes in structural
abnormalities of the prostate were found after 2 yr of treat-
ment, at partial variance with a previous report (14). It should
be mentioned, however, that our first study included only
patients less than 40 yr of age. The age of the patients plays
a relevant role when prostate dimensions and structure are
investigated, as in humans prostate enlargement starts ap-
proximately at the age of 40 yr and rises from 23% to 88% by
the ninth decade (26, 32). It is thus arguable that in elderly
acromegalic patients prostate enlargement is due to both
GH/IGF-I excess and the physiological age-related changes.
On this basis, it is hard to expect a decrease in prostate
dimension after suppression of GH/IGF-I levels in elderly
patients. In fact, after 2 yr of treatment a significant decrease
in prostate size was only found in well controlled patients
less than 50 yr of age, not in those more than 50 yr, despite
similar decreases in GH, IGF-I, and IGFBP-3 levels. In these
controlled patients, a reduction in prostate volume was ob-
served despite the significant increase in both T and DHT
levels, confirming previous data obtained in another cohort
of younger patients (14). In the small group of patients not
achieving satisfactory disease control during the study pe-
riod, however, no increase in prostate size was observed, and
it should be noted that all 3 elderly patients in this group had
very high prostate volumes at study entry. Together, these
findings suggest that the possibility of documenting changes
in prostate size and structure during a 2-yr period in subjects
over 50 yr of age is unlikely.
With regard to the detection of somatostatin receptors,
primarily subtypes 1 and 2, in stromal cells of benign and
malignant prostate (33–35), it is arguable that the chronic
lanreotide administration could regulate the paracrine-
autocrine pathways of the GH/IGF/IGFBP system within
the gland. Lanreotide treatment can induce a decrease in
prostate dimension by displaying a direct antiproliferative
effect (36), by indirectly suppressing circulating levels of
GH/IGF-I, or both. It should be mentioned that octreotide,
another somatostatin analog, was used together with com-
plete androgen blockade in patients with prostate carcinoma
with beneficial results (37). Lanreotide treatment could also
prevent prostate enlargement by inducing apoptosis of the
mesenchymal tissue and by modifying the hemodynamic
conditions of the local blood circulation (38). As the reduction
in PV was also observed in patients achieving disease control
by surgery alone, the possibility that GH and IGF-I suppres-
sion itself had a direct shrinking effect on the prostate is
highly likely. Finally, in none of the patients were PSA levels,
digital rectal exploration, or TRUS able to detect the occur-
rence of prostatic cancer in young/adult and elderly patients.
In conclusion, the prostate is a primary target tissue of GH
and IGF-I. Chronic suppression of GH and IGF-I levels by
surgery or lanreotide treatment induced a significant de-
crease in PV in the acromegalic patients achieving disease
control, mostly in those less than 50 yr of age and thus not
affected by age-dependent prostate hyperplasia. The inhib-
itory effect of GH and IGF-I suppression on prostate size was
documented despite a significant increase in androgen lev-
els. These data indicate that the GH/IGF-I axis plays a role
in the development of prostate overgrowth in acromegaly;
that it plays a similar role in nonacromegalic subjects cannot
be ruled out.
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